The industry met a new milestone in the regulatory field this part year – 2011 saw a seven year high of FDA approvals with 30 drug approvals. Among those receiving multiple approvals were Johnson & Johnson and GlaxoSmithKline. Will that number stay high in 2012 and in years to come? To find out more, click here.
Obstacles Facing Biosimilars
Still in its infancy in the U.S., the industry faces some growing pains.
Life Science Accelerated
Our experts are dedicated to expediting life science product development regulatory pathways.